ACHE and early-onset autosomal dominant Alzheimer disease: The promising AChE and BChE inhibitory capabilities of our synthesised chromium oxide nanoparticles implies that such NPs could be used therapeutically in neurodegenerative illnesses, including Alzheimer’s disease.